| Baseline | Last visit | P -value |
---|---|---|---|
Male gender, n (%) | 36 (50.0%) | Â | |
Age, years | 49.6 ± 11.7 | 55.9 ± 11.6 |  |
Psoriatic arthritis (PsA) characteristics | Â | Â | Â |
  PsA disease duration, years | 9.2 (2.4 to 14.10) | 15.7 (8.5 to 21.2) |  |
  Tender joint count, 0 to 68 | 2 (0 to 8) | 1 (0 to 4) | 0.033 |
  Swollen joint count, 0 to 66 | 0 (0 to 3) | 0 (0 to 1) | 0.032 |
  Damaged joint count, 0 to 68 | 2 (0 to 5) | 2 (0 to 6) | 0.031 |
  Visual analog scale pain, 0 to 100 | 50 (30 to 66) | 30 (20 to 58) | 0.001 |
  Patients’ global assessment, 0 to 100 | 50 (30 to 60) | 40 (20 to 60) | 0.298 |
  Physicians’ global assessment, 0 to 100 | 20 (0 to 30) | 20 (5 to 35) | 0.683 |
  Psoriasis Area and Severity Index, 0 to 72 | 2.6 (0.9 to 7.5) | 1.8 (0.4 to 6.3) | 0.309 |
  Health assessment questionnaire, 0 to 3 | 0.38 (0.12 to 0.94) | 0.25 (0 to 0.69) | 0.043 |
  Minimal disease activity, n (%) | 16 (22.2%) | 14 (19.4%) | 0.539 |
  Disease Activity in Psoriatic Arthritis, 0 to 164 | 16 (8 to 21) | 11 (6 to 16) | 0.010 |
  Erythrocyte sedimentation rate, mm/1st h | 23 (10 to 37) | 18 (8 to 34) | 0.357 |
  C-reactive protein, mg/dl | 0.4 (0.2 to 1.3) | 0.3 (0.1 to 0.7) | 0.016 |
Cardiovascular risk factors | Â | Â | Â |
  Body weight, kg | 65.2 ± 12.0 | 65.7 ± 11.6 | 0.436 |
  Body height, cm | 161 ± 8 |  | |
  Systolic blood pressure, mmHg | 136 ± 22 | 127 ± 15 | <0.001 |
  Hypertension, n (%) | 36 (50.0%) | 44 (61.1%) | 0.555 |
  Diabetes, n (%) | 16 (44.4%) | 16 (44.4%) | 1.000 |
  Framingham 10-year CVD risk >10%, n (%) | 30 (41.7%) | 36 (50.0%) | 0.316 |
  Total cholesterol, mmol/L | 5.1 ± 0.9 | 4.9 ± 0.8 | 0.073 |
  High-density lipoprotein cholesterol, mmol/L | 1.6 ± 0.5 | 1.4 ± 0.4 | <0.001 |
  Triglycerides, mmol/L | 1.5 ± 0.9 | 1.5 ± 0.9 | 0.558 |
  Fasting glucose, mmol/L | 5.5 ± 1.3 | 5.5 ± 1.6 | 0.861 |
Medications, n (%) | Â | Â | Â |
  Anti-hypertensive drugs | 20 (27.8%) | 42 (58.3%) | <0.001 |
  Statins | 1 (1.4%) | 14 (19.4%) | <0.001 |
  Nonsteroidal anti-inflammatory drugs | 33 (45.8%) | 31 (43.1%) | 0.737 |
  Steroids | 4 (5.6%) | 3 (4.2%) | 0.999 |
  Disease-modifying antirheumatic drugs | 36 (50.0%) | 40 (55.6%) | 0.504 |
  Biologics | 0 (0%) | 11 (15.4%) | 0.001 |